Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638069 | 1.00 | HIF1A (0.49) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL21681323 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL18343133 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL21681292 | 0.90 | HIF1A (0.48) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL18343201 | 0.88 | HIF1A (0.48) | HIF1AHSD17B10KDM4EGAAKMT2A | |
| SCHEMBL18343289 | 0.88 | HIF1A (0.46) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL14241706 | 0.86 | HIF1A (0.52) | HIF1AHSD17B10KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18343362 | 0.86 | LMNA (0.49) | HIF1AHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL21217992 | 0.85 | HIF1A (0.56) | HIF1AKDM4EALDH1A1GAALMNA | |
| SCHEMBL17315510 | 0.84 | HIF1A (0.46) | HIF1AHSD17B10KDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| CN-115385899-A | Deuterated drug of ROCK2 inhibitor belumosudil and application thereof | 药康众拓(江苏)医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | HIF1A 2063/4885HSD17B10 864/4885KDM4E 129/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | HIF1A 1680/4885HSD17B10 814/4885KDM4E 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.